


1618 160



DOCKET NO.: PSU-0016

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Miller, et al.

Serial No.: 09/623,568

Group Art Unit: 1614

Filing Date: August 31, 2000

Examiner: Not Assigned Yet

For: USE OF A HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE  
FOR TREATMENT AND DIAGNOSIS OF CANCER

RECEIVED  
JUN 15 2005  
TECH CENTER 1600/2900

DATE OF DEPOSIT: 6/14/05

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE COMMISSIONER FOR PATENTS,  
P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Janet E. Reed  
REGISTRATION NO.: 36,252

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PETITION FOR WITHDRAWAL OF ABANDONMENT

During a recent review and status check of the above-identified application, Applicants learned that the above-identified application became abandoned for failure to respond to the Notice to File Missing Requirements dated July 11, 2001.

Based on the evidence submitted herewith, Applicants petition that the abandonment asserted by the Office be withdrawn as there is no abandonment in fact.


Submitted herewith is:

- ☒ A copy of the postcard identifying the papers filed and showing the U.S. PTO receipt stamp dated **November 13, 2001**.
- ☒ A copy of the complete response timely filed.
- ☒ A copy of Express Mail Label No. EL899364589 which is the number identified on the first page of the previously filed response showing a written "date in" of November 13, 2001.

- ☒ Applicants authorize the Commissioner to charge Deposit Account No. 23-3050 in the amount of the petition fee. However, as no defect exists in applicant's previous submission, an immediate refund of the petition fee is requested.
- ☒ The Commissioner is hereby authorized to charge payment of the above fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in duplicate.

Date:

6/10/2005



Janet E. Reed

Registration No. 36,252

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



RECEIVED  
JUN 15 2005  
TECH CENTER 1600/2800

RECEIVED BY THE UNITED STATES  
PATENT AND TRADEMARK OFFICE  
Via Express Mail # EL 899364589 US

**Paper:** Transmittal Letter to PCT/DE/EO/US in duplicate; Change of Correspondence Address (1 sh.); Petition for Extension of Time (2 sh.); Transmittal Letter Submitting Sequence Listing (1 sh.); Statement to Support Filing and Submission (1 sh.); sequence listing in written form (8 sh.) and computer readable format (1 diskette); copy of Notification of Missing Requirements (2 sh.); Check for \$200.00.

**Applicant(s):** Barbara MILLER, et al.

**Serial No.:** 09/623,568

**International Filing Date:** 05 March 1999

**Docket No.:** PSU-0016

**Date Sent:** November 13, 2001

JER/vchicchi

RECEIVED BY THE UNITED STATES  
PATENT AND TRADEMARK OFFICE  
Via Express Mail # EL 899364589 US

**Paper:** Transmittal Letter to PCT/DE/EO/US in duplicate; Change of Correspondence Address (1 sh.); Petition for Extension of Time (2 sh.); Transmittal Letter Submitting Sequence Listing (1 sh.); Statement to Support Filing and Submission (1 sh.); sequence listing in written form (8 sh.) and computer readable format (1 diskette); copy of Notification of Missing Requirements (2 sh.); Check for \$200.00.

**Applicant(s):** Barbara MILLER, et al.

**Serial No.:** 09/623,568

**International Filing Date:** 05 March 1999

**Docket No.:** PSU-0016

**Date Sent:** November 13, 2001

JER/vchicchi

JCO7 Rec'd PCT/PTO 13 NOV 2001

RECEIVED  
JUN 15 2005  
TECH CENTER 1600/2800



EL 899364589 US

RECEIVED  
JUN 15 2005  
TECH CENTER 1800/2800

**EXPRESS MAIL**  
UNITED STATES POSTAL SERVICE®  
**POST OFFICE TO ADDRESSEE**

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery Next <input type="checkbox"/> Second <input type="checkbox"/>	Flat Rate Envelope <input type="checkbox"/>
Date in Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$
Time in <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight lbs. ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Total Postage & Fees \$

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time Mo. Day <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Delivery Attempt	Time Mo. Day <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Delivery Date	Time Mo. Day <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
<input type="checkbox"/> <b>WAIVER OF SIGNATURE (Domestic Only):</b> Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.		
NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		

Mailing Label  
Label 11-F August 2000

**CUSTOMER USE ONLY**  
METHOD OF PAYMENT: Express Mail Corporate Acct. No. **X191468**

FROM: (PLEASE PRINT) **215 568 3100**  
PHONE ( )  
**WOODCOCK WASHBURN KURTZ MACKIE**  
**1 LIBERTY PL FL 40**  
**PHILADELPHIA PA 19103-7301**

Federal Agency Acct. No. or Postal Service Acct. No.

TO: (PLEASE PRINT) PHONE ( )  
**ASSISTANT COMMISSIONER FOR PATENTS**  
**ATTN: BOX PCT/RO/US**  
**WASHINGTON DC 20231-0001**

F02  
T12

26/ 200

**PRESS HARD.**

You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 [www.usps.com](http://www.usps.com)



**EXPRESS MAIL**  
UNITED STATES POSTAL SERVICE®  
**POST OFFICE TO ADDRESSEE**

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery Next <input type="checkbox"/> Second <input type="checkbox"/>	Flat Rate Envelope <input type="checkbox"/>
Date in Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$12.45
Time in <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight lbs. ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Total Postage & Fees \$12.45

<input type="checkbox"/> <b>WAIVER OF SIGNATURE (Domestic Only):</b> Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.		
NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		

SEE REVERSE SIDE FOR  
SERVICE GUARANTEE AND LIMITS  
ON INSURANCE COVERAGE



Customer Copy  
Label 11-F August 2000

**CUSTOMER USE ONLY**  
METHOD OF PAYMENT: Express Mail Corporate Acct. No. **X191468**

FROM: (PLEASE PRINT) **215 568 3100**  
PHONE ( )  
**WOODCOCK WASHBURN KURTZ MACKIE**  
**1 LIBERTY PL FL 40**  
**PHILADELPHIA PA 19103-7301**

Federal Agency Acct. No. or Postal Service Acct. No.

TO: (PLEASE PRINT) PHONE ( )  
**ASSISTANT COMMISSIONER FOR PATENTS**  
**ATTN: BOX PCT/RO/US**  
**WASHINGTON DC 20231-0001**

F02  
T12

26/

FOR PICKUP OR TRACKING CALL 1-800-222-1811 [www.usps.com](http://www.usps.com)



BEST AVAILABLE COPY

FORM PTO-1390

JUN 13 2005

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  
TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY DOCKET NUMBER  
PSU-0016

U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5)  
09/623,568

INTERNATIONAL APPLICATION NO.  
PCT/US99/04996

INTERNATIONAL FILING DATE  
05 March 1999

PRIORITY DATE CLAIMED  
05 March 1998

TITLE OF INVENTION USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR TREATMENT AND DIAGNOSIS OF CANCER

APPLICANT(S) FOR DO/EO/US Barbara MILLER, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) 35 U.S.C. 371(c)(4).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 5.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
  - Transmittal Letter submitting Sequence Listing.
  - Sequence Listing in computer readable form (1 diskette) and written form (8 sheets).
  - Statement to Support Filing and Submission.
  - Petition for Extension of Time.
  - Change of Correspondence Address.
  - Copy of Notification of Missing Requirements.

RECEIVED

JUN 15 2005

TECH CENTER 1600/2900

EXPRESS MAIL Mailing Label No. 899364589 US  
Date of Deposit: 13 November 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

U.S. APPLICATION NO. (if known 37 C.F.R. 1.5)  
09/623,568

INTERNATIONAL APPLICATION NO.  
PCT/US99/04996

ATTORNEY DOCKET NUMBER  
PSU-0016

17. The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO.....\$1,040.00

International preliminary examination fee (37 CFR 1.482 not paid to USPTO  
but International Search Report has been prepared by the EPO or JPO.....\$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$740.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) but  
all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and  
all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than \_ 20 \_ 30 months from  
the earliest claimed priority date (37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate		
Total claims	- 20 =		X \$18.00	\$	
Independent Claims	- 3 =		x \$84.00	\$	
Multiple dependent claims(s) (if applicable)			+ \$280.00	\$	

TOTAL OF ABOVE CALCULATIONS =

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are  
reduced by 1/2.

SUBTOTAL =

Processing fee of \$130.00 for furnishing the English translation later than \_ 20 \_ 30 months  
from the earliest claimed priority date (37 CFR 1.492(f)).

TOTAL NATIONAL FEE =

Fee for Petition for Extension of Time (Small Entity) + \$200.00

TOTAL FEES ENCLOSED = \$200.00

Amount to be:  
refunded \$  
charged \$

a. ☒ A check in the amount of \$ 200.00 to cover the above fee is enclosed.

b. ☐ Please charge my Deposit Account No. 23-3050 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-3050. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Janet E. Reed  
Woodcock Washburn LLP  
One Liberty Place - 46th Floor

SIGNATURE

Janet E. Reed  
NAME

JUN 13 2005

JUL 16 2001



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/623568	MILLER	98-1895
INTERNATIONAL APPLICATION NO.		
PCT/US99/04996		
I.A. FILING DATE		PRIORITY DATE
05 MAR 99		05 MAR 98

THE PENNSYLVANIA STATE UNIVERSITY  
113 TECHNOLOGY CENTER  
UNIVERSITY PARK, PA 16802

DATE MAILED: 11 JUL 2001

**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> U.S. Basic National Fee.  | <input type="checkbox"/> Indication of Small Entity Status.                         |
| <input checked="" type="checkbox"/> Copy of the international application.  | <input type="checkbox"/> Translation of the international application into English. |
| <input checked="" type="checkbox"/> Oath or Declaration of inventor(s).   | <input type="checkbox"/> Translation of Article 19 amendments into English.         |
| <input type="checkbox"/> Copy of Article 19 amendments.   | <input type="checkbox"/> Other:   |
| <input checked="" type="checkbox"/> Priority Document.  |   |
| <input type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any.     |   |
| <input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. |   |

2. ☒ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.

- ☐ U.S. Basic National Fee. ☐ Copy of the international application.

3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
- ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
- ☐ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
- ☐ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4. Additional claim fees of \$ \_\_\_\_\_ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

**ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

**A copy of this notice MUST be returned with this response.**

Enclosed: ☐ PCT/DO/EO/917  
☐ PTO-875

☐ Notice of Defective Translation  
☒ PCT/DO/EO/920

Pat Booker, Paralegal


Telephone: (703) 306-3738

FORM PCT/DO/EO/905 (March 2001)

RECEIVED

JUN 16 2005

TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/623568	MILLER	B 98-1895
INTERNATIONAL APPLICATION NO.		
PCT/US99/04996		
I.A. FILING DATE		PRIORITY DATE
05 MAR 99		05 MAR 98

DATE MAILED: 11 JUL 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☐ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE  
CALL:**

(703) 308-4216, for Rules interpretation,  
(703) 308-4212, for CRF submission help,  
(703) 287-0200, for PatentIn software help.

Pat Booker, Paralegal

Telephone: (703) 305-3738

FORM PCT/DO/EO/920 (March 2001)

TECH CENTER 1600/2900

JUN 16 2005

RECEIVED



RECEIVED

JUN 15 2005

DOCKET NO.: PSU-0016

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Barbara MILLER, et al.

Serial No.: 09/623,568

Group Art Unit: not yet known

Intl. Appln. No.: PCT/US99/04996

Int. Filing Date: 05 March 1999

Examiner: submitted herewith

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR  
TREATMENT AND DIAGNOSIS OF CANCER

Assistant Commissioner for Patents  
Washington DC 20231

**CHANGE OF CORRESPONDENCE ADDRESS**

Please change the Correspondence Address for the above-identified application to:

**Woodcock Washburn LLP  
One Liberty Place - 46<sup>th</sup> Floor  
Philadelphia, PA 19103**

I am the:

- ☐ Applicant
- ☐ Assignee of record of the entire interest. Statement under 37 CFR 3.73(b) is enclosed.
- ☒ Attorney or agent of record

Date:

11/13/01

  
Janet E. Reed

Registration No. 36,252

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439


**RECEIVED**

JUN 15 2005

DOCKET NO.: PSU-0016

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Barbara MILLER, et al.

U.S. Serial No.: 09/623,568

Group Art Unit: not yet known

Intl. Application No.: PCT/US99/04996

Intl. Filing Date: 05 March 1999

Examiner: not yet assigned

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR  
TREATMENT AND DIAGNOSIS OF CANCER

Assistant Commissioner for Patents  
Washington DC 20231

**PETITION FOR EXTENSION OF TIME**

Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Notification of Missing Requirements of **July 11, 2001** to and through **November 11, 2001** comprising an extension of the shortened statutory period of **two (2) month(s)**:


	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	FEE	RATE	FEE
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME	\$55	\$	\$110	\$
<input checked="" type="checkbox"/> TWO MONTH EXTENSION OF TIME	\$200	\$200	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME	\$460	\$	\$920	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME	\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME	\$980	\$	\$1960	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID	minus	(\$ )	minus	(\$ )
TOTAL FEE DUE		\$200		

- ☐ An extension for \_\_\_\_\_ has already been secured and the fee paid therefore of \$\_\_\_\_ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$\_\_\_\_\_

- ☒ A check in the amount of \$ 200.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.
- ☐ Please charge my Deposit Account No. 23-3050 in the amount of \$\_\_\_\_.
- This sheet is attached in duplicate.

Date: 11/13/01

  
Janet E. Reed  
Registration No. 36,252

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439


RECEIVED

JUN 15 2005.

TECH CENTER 1600/2900

PSU-0016

IN THE UNITED STATES RECEIVING OFFICE  
Before the United States Receiving Office  
for the Patent Cooperation Treaty



In re application of:

Barbara MILLER, et al.

U.S. Serial No.: 09/623,568

International Application No.: PCT/US99/04996

International Filing Date: 05 March 1999

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR  
TREATMENT AND DIAGNOSIS OF CANCER


Assistant Commissioner for Patents  
BOX PCT DO/EO/US  
Washington, DC 20231

TRANSMITTAL LETTER SUBMITTING SEQUENCE LISTING

Applicant submits herewith the Sequence Listing in written (8 sheets) and computer readable form (1 diskette), the contents of which are the same.

The enclosed Sequence Listing does not go beyond the disclosure in the international application as filed.

Respectfully submitted,

  
Janet E. Reed  
Registration No. 36,252

/vc

Enc.: 1 Diskette ; 8 sheets sequence listing  
Date: 13 November 2001  
WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
(215) 568-3100



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 15 2005

TECH CENTER 1600/2900

In Re Application of:

Barbara MILLER, et al.

U.S. Serial No.: 09/623,568

Intl. Appln. No.: PCT/US99/04996

Group Art Unit: not yet known

Int. Filing Date: 05 March 1999


Examiner: not yet assigned

For: USE OF HUMAN HOMOLOG OF A NUCLEAR MIGRATION GENE FOR  
TREATMENT AND DIAGNOSIS OF CANCERAssistant Commissioner for Patents  
Washington DC 20231STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 CFR §§ 1.821 THROUGH 1.825

- ☒ I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- ☐ I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- ☐ I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ☐ I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- ☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- ☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Date:

11/13/01

  
Janet E. Reed  
Registration No. 36,252Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Tel: (215) 568-2100



SEQUENCE LISTING

RECEIVED

JUN 15 2005

TECH CENTER 1600/2900

<110> Miller, Barbara  
Osmani, Stephen  
Clawson, Gary  
Zhang, Min-Ying  
Norris, James

<120> Use of Human Homolog Of A Nuclear Migration Gene For Treatment And Diagnosis Of Cancer

<130> PSU-0016

<140> 09/623,568

<141> 2001-03-23

<150> 60/076,885

<151> 1998-03-05

<150> PCT US99/04996

<151> 1999-03-05

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 14

<212> PRT

<213> artificial Sequence

<220>

<223> Peptide

<400> 1

Gly Cys Met Val Glu Lys Met Met Tyr Asp Gln Arg Gln Lys  
1 5 10

<210> 2

<211> 15

<212> PRT

<213> artificial Sequence

<220>

<223> Peptide

<400> 2

Asn Gly Ser Leu Asp Ser Pro Gly Lys Gln Asp Thr Glu Glu Asp  
1 5 10 15

<210> 3

<211> 24

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 3

ttctgttcgt ctgaagttgg cagc

24

<210> 4

<211> 24

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 4

caatgaagtg aaggtggagg agag

24

<210> 5

<211> 38

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 5

aaggtaccaa gatggactcc ccagggaagc aggatact

38

<210> 6

<211> 32

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 6

aaggatccaa gaaagttggg tgggtgcagc tc

32

<210> 7

<211> 20

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 7

gaaagtcgga ggttcgaaga

20

<210> 8

<211> 20

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 8

accaactaag aacggccatg

20

<210> 9

<211> 24

<212> DNA

<213> artificial Sequence

<220>

<223> Oligonucleotide

<400> 9

agcaacatgc cgtcgaaccg ctcc

24

<210> 10  
 <211> 24  
 <212> DNA  
 <213> artificial Sequence

<220>  
 <223> Oligonucleotide

<400> 10  
 ggagcgggttc gacggcatgt tgct 24

<210> 11  
 <211> 1281  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 ctagagtgc gagctccggg acgtggatcg gagccggcgc gatgggcgga gagcaggagg 60  
 aggagcgggt cgacggcatg ttgctggcca tggctcagca gcacgagggc ggcgtgcagg 120  
 agcttgatgaa caccttcttc agcttccttc gacgaaaac agactttttc attggaggag 180  
 aagaagggat ggcagagaag cttatcacac agactttcag ccaccacaat cagctggcac 240  
 agaagacccg gcgggagaag agagcccggc aggaggccga gcggcgggag aaggcggagc 300  
 gggcggccag actggccaag gaagccaagt cagagacctc agggccccag atcaaggagc 360  
 taactgatga agaggcagag aggctgcagc tagagattga ccagaaaaag gatgcagaga 420  
 atcatgaggc ccagctcaag aacggcagcc ttgactcccc aggggaagcag gatactgagg 480  
 aagatgagga ggaagatgag aaggacaaag gaaaactgaa gcccaaccta ggcaacgggg 540  
 cagacctgcc caattaccgc tggaccaga ccctgtcgga gctggacctg gcggtccctt 600  
 tctgtgtgaa cttccggctg aaagggaagg acatggtggt ggacatccag cggcggcacc 660  
 tccgggtggg gctcaagggg cagccagcga tcattgatgg ggagctctac aatgaagtga 720  
 aggtggagga gagctcgtgg ctcatgagg acggcaaggt ggtgactgtg catctggaga 780  
 agatcaataa gatggagtgg tggagccgct tgggtgccag tgaccctgag atcaacacca 840  
 agaagattaa ccctgagaat tccaagctgt cagacctgga cagtgaact cgcagcatgg 900  
 tggaaaagat gatgtatgac cagcgacaga agtccatggg gctgccaaact tcagacgaac 960  
 agaagaaaca ggagattctg aagaagttca tggatcaaca tccggagatg gatTTTTCCA 1020  
 aggctaaatt caactagccc ctgttttttc ctccctgaac tcttggggct gagctgcaac 1080  
 caccctaatt tctttccac tcttctctgg gacttgtggg cctcagggct tggggcaggc 1140  
 atgggactgg ccaggcaca caggtcccg ggcatcagga gaaaggctgg gtcttgggac 1200  
 cttgtcctcc ccagttggcc tactgttaca cattaacacg atttgccag ctcaaaaaaa 1260  
 aaaaaaaaaa aaaaaaaaaa a 1281

<210> 12  
 <211> 331  
 <212> PRT  
 <213> Homo sapiens



<400> 12

Met Gly Gly Glu Gln Glu Glu Glu Arg Phe Asp Gly Met Leu Leu Ala  
1 5 10 15

Met Ala Gln Gln His Glu Gly Gly Val Gln Glu Leu Val Asn Thr Phe  
20 25 30

Phe Ser Phe Leu Arg Arg Lys Thr Asp Phe Phe Ile Gly Gly Glu Glu  
35 40 45

Gly Met Ala Glu Lys Leu Ile Thr Gln Thr Phe Ser His His Asn Gln  
50 55 60

Leu Ala Gln Lys Thr Arg Arg Glu Lys Arg Ala Arg Gln Glu Ala Glu  
65 70 75 80

Arg Arg Glu Lys Ala Glu Arg Ala Ala Arg Leu Ala Lys Glu Ala Lys  
85 90 95

Ser Glu Thr Ser Gly Pro Gln Ile Lys Glu Leu Thr Asp Glu Glu Ala  
100 105 110

Glu Arg Leu Gln Leu Glu Ile Asp Gln Lys Lys Asp Ala Glu Asn His  
115 120 125

Glu Ala Gln Leu Lys Asn Gly Ser Leu Asp Ser Pro Gly Lys Gln Asp  
130 135 140

Thr Glu Glu Asp Glu Glu Glu Asp Glu Lys Asp Lys Gly Lys Leu Lys  
145 150 155 160

Pro Asn Leu Gly Asn Gly Ala Asp Leu Pro Asn Tyr Arg Trp Thr Gln  
165 170 175

Thr Leu Ser Glu Leu Asp Leu Ala Val Pro Phe Cys Val Asn Phe Arg  
180 185 190

Leu Lys Gly Lys Asp Val Val Val Asp Ile Gln Arg Arg His Leu Arg  
195 200 205

Val Gly Leu Lys Gly Gln Pro Ala Ile Ile Asp Gly Glu Leu Tyr Asn  
210 215 220

Glu Val Lys Val Glu Glu Ser Ser Trp Leu Ile Glu Asp Gly Lys Val  
225 230 235 240

Val Thr Val His Leu Glu Lys Ile Asn Lys Met Glu Trp Trp Ser Arg  
245 250 255

Leu Val Ser Ser Asp Pro Glu Ile Asn Thr Lys Lys Ile Asn Pro Glu  
Page 4

260

265

270

Asn Ser Lys Leu Ser Asp Leu Asp Ser Glu Thr Glu Ser Met Val Glu  
 275 280 285

Lys Met Met Tyr Asp Gln Arg Gln Lys Ser Met Gly Leu Pro Thr Ser  
 290 295 300

Asp Glu Gln Lys Lys Gln Glu Ile Leu Lys Lys Phe Met Asp Gln His  
 305 310 315 320

Pro Glu Met Asp Phe Ser Lys Ala Lys Phe Asn  
 325 330

<210> 13  
 <211> 332  
 <212> PRT  
 <213> Rattus rattus

<400> 13

Met Gly Gly Glu Gln Glu Glu Arg Phe Asp Gly Met Leu Leu Ala  
 1 5 10 15

Met Ala Gln Gln His Glu Gly Gly Val Gln Glu Leu Val Asn Thr Phe  
 20 25 30

Phe Ser Phe Leu Arg Arg Lys Thr Asp Phe Phe Ile Gly Gly Glu Glu  
 35 40 45

Gly Met Ala Glu Lys Leu Ile Thr Gln Thr Phe Asn His His Asn Gln  
 50 55 60

Leu Ala Gln Lys Ala Arg Arg Glu Lys Arg Ala Arg Gln Leu Thr Glu  
 65 70 75 80

Arg Arg Glu Lys Ala Glu Arg Ala Ala Arg Leu Ala Lys Glu Ala Lys  
 85 90 95

Ala Glu Thr Pro Gly Pro Gln Ile Lys Glu Leu Thr Asp Leu Lys Ala  
 100 105 110

Glu Arg Leu Gln Leu Glu Ile Asp Gln Lys Lys Asp Ala Glu Asn His  
 115 120 125

Glu Val Gln Leu Lys Asn Gly Ser Leu Asp Ser Pro Gly Lys Gln Asp  
 130 135 140

Ala Leu Leu Glu Glu Asp Glu Glu Asp Glu Lys Asp Lys Gly Lys Leu  
 145 150 155 160

Lys Pro Asn Leu Gly Asn Gly Ala Asp Leu Pro Asn Tyr Arg Trp Thr  
 165 170 175

Gln Thr Leu Ser Phe Leu Asp Leu Ala Val Pro Phe Arg Val Ser Phe  
 180 185 190

Arg Leu Lys Gly Lys Gln Val Val Val Asp Ile Gln Arg Arg His Leu  
 195 200 205

Arg Val Gly Leu Lys Gly Gln Ala Pro Val Ile Asp Gly Glu Leu Tyr  
 210 215 220

Asn Glu Val Lys Val Glu Glu Ser Ser Trp Leu Ile Glu Asp Gly Lys  
 225 230 235 240

Val Val Thr Val His Leu Glu Lys Ile Asn Lys Met Glu Trp Trp Asn  
 245 250 255

Arg Leu Val Thr Ser Asp Pro Glu Ile Asn Thr Lys Lys Ile Asn Pro  
 260 265 270

Glu Asn Ser Lys Leu Ser Asp Leu Asp Ser Glu Thr Arg Ser Met Val  
 275 280 285

Glu Lys Met Met Tyr Asp Gln Arg Gln Lys Ser Met Gly Leu Pro Thr  
 290 295 300

Ser Asp Glu Gln Lys Lys Gln Glu Ile Leu Lys Lys Phe Met Asp Gln  
 305 310 315 320

His Pro Glu Met Asp Phe Ser Lys Ala Lys Phe Asn  
 325 330

<210> 14  
 <211> 202  
 <212> PRT  
 <213> Aspergillus nidulans

<400> 14

Met Ser Glu Gln Glu Pro Ser Ser Ala Asp Leu Ala Ala Arg Glu Ala  
 1 5 10 15

Glu Glu Lys Gln Arg Lys Ala Ala Glu Glu Ala Glu Gln Ala Thr Leu  
 20 25 30

Pro Tyr Lys Asn Thr Gln Thr Ile Arg Asp Val Asp Val Phe Thr Thr  
 35 40 45

Ile Pro Val Ser Ala Asn Leu Lys Gly Arg Asp Leu Asp Val Val Leu  
 50 55 60

Lys Lys Asp Ser Ile Lys Val Lys Val Lys Gly Glu Asn Gly Glu Val  
 65 70 75 80

Phe Ile Asp Gly Gln Phe Pro His Pro Ile Lys Pro Ser Glu Ser Ser  
85 90 95

Trp Thr Leu Glu Thr Thr Ser Lys Pro Pro Phe Thr Gly Lys Glu Val  
100 105 110

Ser Ile His Leu Asp Lys Val Asn Gln Met Glu Trp Trp Ala Met Val  
115 120 125

Val Thr Thr Ala Pro Lys Ile Asp Val Ser Lys Ile Thr Phe Glu Asn  
130 135 140

Ser Ser Leu Ser Asp Leu Asp Gly Glu Thr Arg Ala Met Val Glu Lys  
145 150 155 160

Met Met Tyr Asp Gln Arg Gln Lys Glu Met Gly Ala Pro Thr Ser Asp  
165 170 175

Glu Gln Arg Lys Met Asp Ile Leu Lys Lys Phe Gln Lys Glu His Pro  
180 185 190

Glu Met Asp Phe Ser Asn Ala Lys Ile Gly  
195 200

<210> 15  
<211> 93  
<212> PRT  
<213> artificial Sequence

<220>  
<223> Consensus Sequence

<400> 15

Ser Phe Asp Glu Lys Glu Ala Leu Pro Tyr Asn Thr Gln Thr Asp Val  
1 5 10 15

Leu Lys Gly Asp Val Val Lys Ile Asp Gly Lys Glu Ser Ser Trp Glu  
20 25 30

Gly Lys Val His Leu Lys Asn Met Glu Trp Trp Val Pro Ile Lys Ile  
35 40 45

Pro Glu Asn Ser Leu Ser Asp Leu Asp Glu Thr Arg Met Tyr Glu Lys  
50 55 60

Met Met Tyr Asp Gln Arg Gln Lys Met Gly Pro Thr Ser Asp Glu Gln  
65 70 75 80

Lys Ile Leu Lys Lys Phe His Phe Glu Met Asp Phe Ser  
85 90

<210> 16

<211> 12  
<212> PRT  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (9)..(9)  
<223> X=Any Amino Acid

<220>  
<221> misc\_feature  
<222> (11)..(11)  
<223> X=Any Amino Acid

<400> 16

Met Val Glu Lys Met Met Tyr Asp Xaa Arg Xaa Lys  
1 5 10